2024-18264. Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Selected Microbial Agents That Cause Acute Febrile Illness  

  • Table 1—Device To Detect and Identify Selected Microbial Agents That Cause Acute Febrile Illness Risks and Mitigation Measures

    Identified risks Mitigation measures
    Risk of an inaccurate test result (false positive or false negative result) leading to improper patient management Certain labeling information, including certain limiting statements and performance information; Certain design verification and validation, including certain analytical studies and clinical studies; and Use of certain specimen collection devices.
    Misinterpretation of test results leading to misdiagnosis and associated risk of false test results Certain labeling information, including certain limiting statements and performance information; and Certain design verification and validation, including certain analytical studies and clinical studies.
    Failure to correctly operate the device leading to inaccurate test results Certain labeling information, including certain limiting statements and performance information; Certain design verification and validation, including certain analytical studies and clinical studies; and Use of certain specimen collection devices.

Document Information

Effective Date:
8/16/2024
Published:
08/16/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-18264
Dates:
This order is effective August 16, 2024. The classification was applicable on November 20, 2020.
Pages:
66556-66558 (3 pages)
Docket Numbers:
Docket No. FDA-2024-N-3358
Topics:
Biologics, Laboratories, Medical devices
PDF File:
2024-18264.pdf
CFR: (1)
21 CFR 866